These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
306 related articles for article (PubMed ID: 25934338)
1. New approaches for cancer immunotherapy. Karlitepe A; Ozalp O; Avci CB Tumour Biol; 2015 Jun; 36(6):4075-8. PubMed ID: 25934338 [TBL] [Abstract][Full Text] [Related]
2. The expanding role of immunotherapy. Martin-Liberal J; Ochoa de Olza M; Hierro C; Gros A; Rodon J; Tabernero J Cancer Treat Rev; 2017 Mar; 54():74-86. PubMed ID: 28231560 [TBL] [Abstract][Full Text] [Related]
3. Monoclonal antibodies in cancer immunotherapy. Kimiz-Gebologlu I; Gulce-Iz S; Biray-Avci C Mol Biol Rep; 2018 Dec; 45(6):2935-2940. PubMed ID: 30311129 [TBL] [Abstract][Full Text] [Related]
4. New Approaches for Immune Directed Treatment for Ovarian Cancer. Hardwick N; Frankel PH; Cristea M Curr Treat Options Oncol; 2016 Mar; 17(3):14. PubMed ID: 26942589 [TBL] [Abstract][Full Text] [Related]
5. Future Research Goals in Immunotherapy. Hulett TW; Fox BA; Messenheimer DJ; Marwitz S; Moudgil T; Afentoulis ME; Wegman KW; Ballesteros-Merino C; Jensen SM Surg Oncol Clin N Am; 2019 Jul; 28(3):505-518. PubMed ID: 31079803 [TBL] [Abstract][Full Text] [Related]
6. Addressing cancer immunotherapy research in Iran: adoptive cell therapy on the horizon. Khatami F; Torabi-Rahvar M; Kiani J; Naderi M; Ahmadbeigi N Cytotherapy; 2018 Oct; 20(10):1227-1237. PubMed ID: 30266521 [TBL] [Abstract][Full Text] [Related]
7. Immunotherapeutic strategies to target prognostic and predictive markers of cancer. Magee MS; Snook AE; Marszalowicz GP; Waldman SA Biomark Med; 2013 Feb; 7(1):23-35. PubMed ID: 23387482 [TBL] [Abstract][Full Text] [Related]
9. Current modalities in cancer immunotherapy: Immunomodulatory antibodies, CARs and vaccines. Lohmueller J; Finn OJ Pharmacol Ther; 2017 Oct; 178():31-47. PubMed ID: 28322974 [TBL] [Abstract][Full Text] [Related]
10. Update on Mucin-1 immunotherapy in cancer: a clinical perspective. Rivalland G; Loveland B; Mitchell P Expert Opin Biol Ther; 2015; 15(12):1773-87. PubMed ID: 26453294 [TBL] [Abstract][Full Text] [Related]
11. Combinatorial treatments including vaccines, chemotherapy and monoclonal antibodies for cancer therapy. Baxevanis CN; Perez SA; Papamichail M Cancer Immunol Immunother; 2009 Mar; 58(3):317-24. PubMed ID: 18704409 [TBL] [Abstract][Full Text] [Related]
12. Monoclonal antibodies: versatile platforms for cancer immunotherapy. Weiner LM; Surana R; Wang S Nat Rev Immunol; 2010 May; 10(5):317-27. PubMed ID: 20414205 [TBL] [Abstract][Full Text] [Related]
13. Current Trends and Innovative Approaches in Cancer Immunotherapy. Kim J; Maharjan R; Park J AAPS PharmSciTech; 2024 Jul; 25(6):168. PubMed ID: 39044047 [TBL] [Abstract][Full Text] [Related]
14. Immunotherapy as an Option for Cancer Treatment. Rusch T; Bayry J; Werner J; Shevchenko I; Bazhin AV Arch Immunol Ther Exp (Warsz); 2018 Apr; 66(2):89-96. PubMed ID: 29026920 [TBL] [Abstract][Full Text] [Related]
15. Human Tumor Antigens and Cancer Immunotherapy. Vigneron N Biomed Res Int; 2015; 2015():948501. PubMed ID: 26161423 [TBL] [Abstract][Full Text] [Related]
16. Cancer immunotherapy. Schuster M; Nechansky A; Kircheis R Biotechnol J; 2006 Feb; 1(2):138-47. PubMed ID: 16892244 [TBL] [Abstract][Full Text] [Related]
17. The immunotherapy era of myeloma: monoclonal antibodies, vaccines, and adoptive T-cell therapies. Hoyos V; Borrello I Blood; 2016 Sep; 128(13):1679-87. PubMed ID: 27506540 [TBL] [Abstract][Full Text] [Related]
18. Cancer immunotherapy: the beginning of the end of cancer? Farkona S; Diamandis EP; Blasutig IM BMC Med; 2016 May; 14():73. PubMed ID: 27151159 [TBL] [Abstract][Full Text] [Related]